China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd has announced further details on its proposed acquisition of Green Cross HK, revealing that Green Cross HK’s long-term equity investments have an appraised value of RMB 1.44 billion as of the valuation date. The valuation takes into account different risk parameters between Hong Kong and mainland China and separately assesses the value of Green Cross HK’s two distinct business segments – blood products and import agency sales. The company confirms the valuation and profit forecast in the Appraisal Report were prepared with due diligence.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
